Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes Drug's hidden risk: when low fluids and insulin spark dangerous ketones

NCT ID NCT07053306

Recruiting now Knowledge-focused Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates why SGLT2 inhibitors, a common diabetes medication, can sometimes lead to ketoacidosis—a dangerous buildup of acids in the blood. Researchers suspect it only happens when patients also have low blood volume and low insulin levels. Adults with type 2 diabetes will receive a single dose of empagliflozin, and scientists will measure how their bodies produce and break down ketones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin (a diabetes medication that lowers blood sugar by increasing glucose excretion in urine)
What this could lead to
If confirmed, this could help predict and prevent ketoacidosis in people with type 2 diabetes taking SGLT2 inhibitors.
What could go wrong
This is a small, early-phase mechanistic study, not a treatment trial. Results may not apply to all patients or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Diabetes Institute/UH

    RECRUITING

    San Antonio, Texas, 78229-3900, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.